2010
DOI: 10.1002/lary.21060
|View full text |Cite
|
Sign up to set email alerts
|

Cochlear implantation in patients with autoimmune inner ear disease including cogan syndrome: A comparison with age‐ and sex‐matched controls

Abstract: These findings indicate that CM has the potential to prevent secondary bacterial infections in RV-infected HNECs by inhibiting the expression of Fn and CEACAM, thereby interfering with bacterial adhesion.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

2
30
0
1

Year Published

2014
2014
2022
2022

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 35 publications
(33 citation statements)
references
References 14 publications
2
30
0
1
Order By: Relevance
“…Although there may be higher rates of fibrosis and ossification within the cochlea, patients with AIED perform at least as well as matched control patients, with other etiologies of hearing loss, after implantation (52,53).…”
Section: Discussionmentioning
confidence: 92%
“…Although there may be higher rates of fibrosis and ossification within the cochlea, patients with AIED perform at least as well as matched control patients, with other etiologies of hearing loss, after implantation (52,53).…”
Section: Discussionmentioning
confidence: 92%
“…Wang et al [18] reported 18 patients with autoimmune inner ear disease. Intraoperatively, one patient was found to have ossification of the basal turn of the scala tympani, and partial electrode insertion was performed.…”
Section: Discussionmentioning
confidence: 99%
“…40 Cochlear implants have been shown to be beneficial in patients with end-stage hearing loss from CS. 41,42 This surgical intervention is equally as effective in CS as in non-AIED hearing loss and significantly improves the quality of life of these patients. 42 There are no trials to guide treatment of vasculitis in CS.…”
Section: Managementmentioning
confidence: 97%
“…41,42 This surgical intervention is equally as effective in CS as in non-AIED hearing loss and significantly improves the quality of life of these patients. 42 There are no trials to guide treatment of vasculitis in CS. Strategies parallel the paradigms of other large vessel vasculitites.…”
Section: Managementmentioning
confidence: 97%